We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution

By LabMedica International staff writers
Posted on 16 Nov 2026

Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring. More...

Traditional mass spectrometry methods often require specialized personnel and complex manual workflows, creating barriers to routine laboratory use. A newly authorized platform now brings mass spectrometry together with an automated, standardized workflow for routine clinical testing.

Roche has received U.S. Food and Drug Administration De Novo authorization for the cobas pro i 601 platform with the Ionify Gabapentin assay, components of its cobas® Mass Spec solution. The authorization expands Roche’s mass spectrometry menu into therapeutic drug monitoring. The U.S. menu also includes 25-Hydroxy Vitamin D total and steroid hormone testing assays, such as estradiol and 17-Hydroxyprogesterone.

The cobas Mass Spec solution combines the high specificity, sensitivity, and accuracy of mass spectrometry with an automated, standardized workflow. This configuration is designed to simplify testing that has traditionally been complex, while retaining the analytical capabilities associated with mass spectrometry. The Ionify Gabapentin assay adds a therapeutic drug monitoring application to the platform.

Roche will use an FDA-authorized Predetermined Change Control Plan to support future clinical mass spectrometry menu expansion. The authorized plan includes expansion of up to 22 Ionify assays on the cobas pro i 601 platform as requirements are met. These additional assays are not yet available and will be introduced in the future as applicable requirements are met.

“Some of the best diagnostic technologies are often very complex and, in the end, don't actually reach patients. Mass spectrometry has long been valued for its analytical performance, but the complexity of traditional workflows has limited its use in routine laboratories. By automating and standardizing this technology, we're helping make sophisticated testing more accessible to laboratories, clinicians and patients who depend on reliable results,” said Dan Malarek, President and CEO of Roche Diagnostics North America.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Connectivity Solution
EKF Link
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.